Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vaccine ; 2024 May 27.
Artigo em Inglês | MEDLINE | ID: mdl-38802292

RESUMO

As dozens of new National Immunization Technical Advisory Groups (NITAGs) were established worldwide in the past decade, and as existing NITAGs continued to play an important role in vaccine policy, global NITAG partners recognized a need for a standardized assessment tool to evaluate and strengthen their functions. This article describes the development of the NITAG Maturity Assessment Tool (NMAT), a stepwise evaluation tool that assesses NITAGs on seven key indicators of structure and process. A draft tool was developed through an iterative, consensus-based process with an expert working group before it was piloted with an economically and geographically diverse convenience sample of NITAGs. The final NMAT is a flexible tool that can be used by in-country or external evaluators to understand NITAG maturity, identify priorities for optimization, and measure the impact of strengthening efforts.

2.
Dev World Bioeth ; 16(2): 70-9, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27378034

RESUMO

There is currently no international consensus around post-trial obligations toward research participants, community members, and host countries. This literature review investigates arguments and attitudes toward post-trial access. The literature review found that academic discussions focused on the rights of research participants, but offered few practical recommendations for addressing or improving current practices. Similarly, there are few regulations or legislation pertaining to post-trial access. If regulatory changes are necessary, we need to understand the current arguments, legislation, and attitudes towards post-trial access and participants and community members. Given that clinical trials conducted in low-income countries will likely continue, there is an urgent need for consideration of post-trial benefits for participants, communities, and citizens of host countries. While this issue may not be as pressing in countries where participants have access to healthcare and medicines through public schemes, it is particularly important in regions where this may not be available.


Assuntos
Ensaios Clínicos como Assunto/ética , Pesquisa Participativa Baseada na Comunidade/ética , Ética em Pesquisa , Guias como Assunto , Acessibilidade aos Serviços de Saúde/ética , Direitos do Paciente/ética , Atitude , Acessibilidade aos Serviços de Saúde/legislação & jurisprudência , Humanos , Legislação como Assunto , Pobreza
3.
BMC Med Ethics ; 16(1): 84, 2015 Dec 02.
Artigo em Inglês | MEDLINE | ID: mdl-26630936

RESUMO

BACKGROUND: While ethicists have for many years called for human subject trial participants and, in some cases, local community members to benefit from participation in pharmaceutical and other intervention-based therapies, little is known about how these discussions are impacting the practice of research ethics boards (REBs) that grant ethical approval to many of these studies. METHODS: Telephone interviews were conducted with 23 REB members from across Canada, a major funder country for human subject research internationally. All interviews were digitally recorded and transcribed verbatim. After coding, the data was analyzed to identify central themes and topics. Themes were identified, application of the themes was confirmed, and these themes were then used to populate the findings of this manuscript. RESULTS: Our analysis of the interviews identified two primary themes when considering what benefits are owed to research participants and their communities. 1) Most study participants felt that given that these studies are led by persons in the role of researcher rather than health care provider, they had a limited obligation to provide benefits to study participants. 2) These REB members were all working in Canada, a high income country where most residents enjoy high levels of access to health care. As a result of this context, the study participants tended to focus on ethical concerns including obtaining informed consent and avoiding undue inducement to participate in research rather than ensuring that study participants directly benefit from successful trials. CONCLUSIONS: Research on REB members' attitudes toward what benefits are owed to study participants and community members is needed in other countries in order to determine how context affects these attitudes.


Assuntos
Pesquisa Biomédica/ética , Ensaios Clínicos como Assunto/ética , Revelação/ética , Comitês de Ética em Pesquisa , Sujeitos da Pesquisa/estatística & dados numéricos , Atitude do Pessoal de Saúde , Canadá/epidemiologia , Eficiência Organizacional , Guias como Assunto , Humanos , Pesquisa Qualitativa , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...